ScholarIQanswers from OpenAlex

One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease

PaperCitations, authors & open-access status

One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease is a paper indexed in ScholarIQ from OpenAlex.

How many citations does One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease have?

ScholarIQcitation count

One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease has 58 citations in the OpenAlex counts ScholarIQ stores.

When was One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease published?

ScholarIQyear

One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease has 2012 year in the ScholarIQ index.

What is the open-access status of One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease?

ScholarIQoa status

One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease has hybrid oa status in the ScholarIQ index.

What is the DOI of One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease?

ScholarIQdoi

The DOI for One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease is on the source record.

What is the PMID of One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease?

ScholarIQpmid

The PMID for One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease is on the source record.

What is the OpenAlex record for One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease?

ScholarIQopenalex

The OpenAlex for One Risk Assessment Tool for Cardiovascular Disease, Type 2 Diabetes, and Chronic Kidney Disease is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial